表紙
市場調查報告書
商品編碼
965933

COVID-19抗原診斷試驗形勢:2021年為止的預測

COVID19 Antigen Diagnostic Test Landscape | Forecasts Through 2021

出版日期: | 出版商: Life Science Intelligence | 英文 30 Pages; 10 Exhibits | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

COVID-19診斷檢驗的全球市場,2020年為160億美金,從2020年到2025年之間預計以6.5%的年複合成長率成長。市場分為分子檢驗,抗原檢驗,及抗體檢驗。最初對抗體檢測的需求已經減弱,這是由於衛生當局將指導方針的重點轉移到了目前無症狀和有症狀的感染病例上。世衛組織宣布將向中低收入國家提供1.2億快速COVID-19檢測。

本報告提供全球COVID-19抗原診斷檢驗市場的相關調查,COVID-19抗原各診斷檢查的市場分析,臨床試驗,法規當局的認證,競爭情形等資訊。

本報告調查對象的企業:

  • Abbott
  • Abbott Diagnostics Scarborough, Inc.
  • Access Bio, Inc
  • AmonMed Biotechnology Co., Ltd
  • AMS UK Ltd.
  • Apollo Biomedical LLC
  • ArcDia International Ltd.
  • Becton, Dickinson and Company (BD)
  • Beijing Abace Biology Co. Ltd
  • Beijing Diagreat Biotechnologies Co., Ltd
  • Beijing Kewei Clinical Diagnostic Reagent Inc.
  • Beijing Savant Biotechnology Co., Ltd
  • BIOHIT HealthCare (Hefei) Co., Ltd
  • Bionote Inc.
  • Boditech Inc.
  • Cepheid
  • CerTest Biotec S.L.
  • Coris BioConcept
  • DiaSorin
  • Edinburgh Genetics Limited
  • GenBody, Inc.
  • Green Cross Medical Science Corp.
  • Hangzhou Deangel Biological Engineering Co., Ltd
  • Hangzhou Genesis Biodetection & Biocontrol Co., Ltd
  • Hologic
  • Humasis
  • Jiangsu Bioperfectus Technologies Co. Ltd
  • JOYSBIO (Tianjin) Biotechnology Co., Ltd
  • Liming Bio-Products Co., Ltd
  • LumiQuick Diagnostics Inc.
  • LumiraDx UK Ltd.
  • Medisys International SA
  • nal von minden GmbH
  • PCL Inc.
  • Precision Biosensor, Inc.
  • Qiagen
  • Quidel Corporation
  • RapiGEN Inc.
  • Roche
  • SD BIOSENSOR, Inc.
  • Shenzhen Bioeasy Biotechnology Co., Ltd
  • ThermoFisher

目錄

市場概要

第1章 摘要整理

第2章 調查範圍

第3章 市場區隔

  • COVID-19抗原診斷檢驗清單
  • 各樣品類型
    • 鼻咽(NP)拭子
    • 中咽(OP)拭子
    • 鼻腔拭子
    • 血液
    • 其他
  • 各手法
    • 分子(PCR)
    • 抗原為基礎
    • 其他
  • 各行動模式
    • 照護現場(POC)
    • 實驗室

第4章 臨床試驗

  • 各狀態
  • 各地區
  • 各贊助商

第5章 法規當局的認證

  • FDA核准
  • CE核准

第6章 競爭情形(主要企業)

目錄

Overview:

The global market for COVID19 Diagnostic Tests was valued at $16B in 2020 and is expected to grow at a CAGR (2020-2025) of 6.5%. The market is segmented into molecular tests, antigen tests, and antibody tests.

Molecular diagnostic tests to diagnose COVID19 were available in the USA a few months after the outbreak in China. On February 4, 2020, the US FDA issued an emergency use authorization (EUA) enabling the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel. Since then authorized molecular laboratories, molecular diagnostic companies, and in-vitro diagnostic companies have developed several COVID19 diagnostic tests. The U.S. FDA has authorized more than 262 coronavirus diagnostic tests under EUAs, which include 205 molecular tests, 51 antibody tests, and 6 antigen tests.

In this new report, LSI provides timely coverage and an assessment of the market opportunities for COVID19 diagnostic tests. The initial demand for antibody tests has subsided due to a shift in the guidance from health authorities to focus on asymptomatic and symptomatic current infection cases. The WHO announced it will provide 120 million rapid COVID-19 tests to low-and middle-income countries. Abbott and Roche have scaled their production of rapid antigen tests and are expected to produce more than 50 million tests per month of BinaxNOW™ COVID-19 Ag Card and STANDARD Q SARS-CoV-2 Rapid Antigen Test respectively. Additionally, Point of Care (POC) antigen tests Veritor™ Plus System from BD, LumiraDx Sars-CoV-2 Ag from LumiraDx, and Sofia SARS Antigen Test were issued FDA EUA and will augment the rapid testing capabilities at hospitals and near-patient CLIA waived settings.

Combination tests that detect common flu A, B, and COVID19 are in demand ahead of the flu season. SARS-CoV-2 and influenza A/B test from Roche and Xpert Xpress SARS-CoV-2, influenza A and B, and respiratory syncytial virus (RSV) from Cepheid (Danaher Company) has been issued FDA EUA.

This report provides data and insight for healthtech executives seeking:

  • Informed decisions for new product development
  • Evaluation of technology transfer opportunities
  • Manufacturing and distribution opportunities
  • Thorough evaluation of progress of vaccine clinical trials
  • Competitive landscape assessment
  • More

Companies Covered:

  • Abbott
  • Abbott Diagnostics Scarborough, Inc.
  • Access Bio, Inc
  • AmonMed Biotechnology Co., Ltd
  • AMS UK Ltd.
  • Apollo Biomedical LLC
  • ArcDia International Ltd.
  • Becton, Dickinson and Company (BD)
  • Beijing Abace Biology Co. Ltd
  • Beijing Diagreat Biotechnologies Co., Ltd
  • Beijing Kewei Clinical Diagnostic Reagent Inc.
  • Beijing Savant Biotechnology Co., Ltd
  • BIOHIT HealthCare (Hefei) Co., Ltd
  • Bionote Inc.
  • Boditech Inc.
  • Cepheid
  • CerTest Biotec S.L.
  • Coris BioConcept
  • DiaSorin
  • Edinburgh Genetics Limited
  • GenBody, Inc.
  • Green Cross Medical Science Corp.
  • Hangzhou Deangel Biological Engineering Co., Ltd
  • Hangzhou Genesis Biodetection & Biocontrol Co., Ltd
  • Hologic
  • Humasis
  • Jiangsu Bioperfectus Technologies Co. Ltd
  • JOYSBIO (Tianjin) Biotechnology Co., Ltd
  • Liming Bio-Products Co., Ltd
  • LumiQuick Diagnostics Inc.
  • LumiraDx UK Ltd.
  • Medisys International SA
  • nal von minden GmbH
  • PCL Inc.
  • Precision Biosensor, Inc.
  • Qiagen
  • Quidel Corporation
  • RapiGEN Inc.
  • Roche
  • SD BIOSENSOR, Inc.
  • Shenzhen Bioeasy Biotechnology Co., Ltd
  • ThermoFisher

Table of Contents

Global COVID19 Antigen Diagnostic Tests Market Overview

1. Executive Summary

2. Scope Of The Report

3. COVID19 Antigen Diagnostic Tests Segmentation

  • 3.1. COVID19 Antigen Diagnostic Tests List (Brief Commentary on Strengths & Weaknesses)
  • 3.2. COVID19 Antigen Diagnostic Tests By Sample Type
    • Nasopharyngeal (NP) Swab
    • Oropharyngeal (OP) Swab
    • Nasal Swab
    • Blood
    • Others
  • 3.3. COVID19 Antigen Diagnostic Tests By Method
    • Molecular (PCR) Testing
    • Antigen-based Testing
    • Others
  • 3.3. COVID19 Antigen Diagnostic Tests By Mode of Operation
    • Point of Care (POC)
    • Laboratory

4. COVID19 Antigen Tests Clinical Trials

  • 4.1. By Status
  • 4.2. By Location
  • 4.3. By Sponsor

5. Regulatory Approval

  • 5.1. FDA Approved COVID19 Antigen Tests
  • 5.2. CE Approved COVID19 Antigen Tests

6 COVID19 Antigen Diagnostic Tests Competitive Landscape (Key Companies)